Xiongjun Wang

12PUBLICATIONS
29CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersPharmaceutical delivery technologiesMajor global burdens of disease
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 30, 2026
α-ketoglutarate accumulation orchestrates immunosuppressive metabolic remodeling to drive cetuximab resistance in metastatic colorectal cancer.

|Dec 23, 2025
FUT2 enhances anti-tumor immunity in pancreatic cancer radiotherapy by driving FBXO2-mediated degradation of NR2F2.

Junguo Chen, Yun Chen, Zhuobin Lin

|Nov 20, 2024
NIT2 dampens BRD1 phase separation and restrains oxidative phosphorylation to enhance chemosensitivity in gastric cancer.

Ziyang Wang, Yuqin Di, Xiangqiong Wen

|Sep 18, 2024
ACSL6-activated IL-18R1-NF-κB promotes IL-18-mediated tumor immune evasion and tumor progression.

Yuqin Di, Ziyang Wang, Jing Xiao

|Mar 11, 2024
Uncovering PROTAC Sensitivity and Efficacy by Multidimensional Proteome Profiling: A Case for STAT3.

Yuying Suo, Daohai Du, Chao Chen

|Jun 06, 2023
Elevated nuclear PIGL disrupts the cMyc/BRD4 axis and improves PD-1 blockade therapy by dampening tumor immune evasion.

Hua Yu, Tiezhu Shi, Linli Yao

Pageof 2

Frequent Collaborators

2 joint publications

Xiangqiong Wen

2 joint publications

Xiang Zhang

2 joint publications

Kunhua Hu

2 joint publications

Yufeng Ding